Gum Tech sales & earnings
This article was originally published in The Tan Sheet
"Growing consumer acceptance of the Zicam brand" spurred sales 17.9% to $5.5 mil. in fourth quarter, up 48.6% to $16.1 mil. for the year, Phoenix-based firm reports Feb. 28. Net loss for FY '01 improved 22.2% to $4.8 mil. Gum Tech's plans for 2002 include corporate name change, continued aggressive advertising, expanded R&D, application for CHPA membership and strengthening of senior management, firm says...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.